T24 In Vivo Anti-Tumor Efficacy Assay

This assay is to provide T24-based In Vivo Anti-Tumor Efficacy Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

T24

Human

The T24 cell line was established from a transitional cell carcinoma of the bladder in a female patient in 1973. Reports in the literature indicated a wide range of tumorigenicity for T24 when injected subcutaneously in immunocompromised murine hosts.

Bladder Cancer

Oncology

In Vivo Anti-Tumor Efficacy Assay

T24-cell based In Vivo Anti-Tumor Efficacy Assay

After positive anti-tumor efficacy data is concluded using in vitro assays, we can start to initiate in vivo anti-tumor efficacy studies. Creative Biolabs offers a wide variety of PDX or CDX models to facilitate the efficacy studies. This assy will be used to evaluate the anti-tumor efficacy of your therapeutic candidates, such as small molecules, antibodies, CARTs or other biologics. Detailed group set up and other plans will be discussed according to your specific requirements.

Oncology In Vivo Assays